Shares of Insulet Co. (NASDAQ:PODD) reached a new 52-week high on Wednesday . The stock traded as high as $115.61 and last traded at $115.51, with a volume of 7851 shares changing hands. The stock had previously closed at $109.77.
Several analysts have weighed in on PODD shares. BidaskClub raised Insulet from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Canaccord Genuity raised their price target on Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Northland Securities reaffirmed a “buy” rating and issued a $100.00 price target on shares of Insulet in a report on Tuesday, February 26th. Oppenheimer set a $100.00 price target on Insulet and gave the company a “hold” rating in a report on Tuesday, February 26th. Finally, BTIG Research raised Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price target on the stock in a report on Monday, May 6th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Insulet currently has an average rating of “Buy” and an average target price of $105.10.
The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 2,288.60 and a beta of 1.12. The company has a quick ratio of 3.71, a current ratio of 4.36 and a debt-to-equity ratio of 2.68.
Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. The company had revenue of $159.56 million for the quarter, compared to analysts’ expectations of $154.66 million. Insulet had a return on equity of 7.01% and a net margin of 2.37%. Insulet’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) EPS. On average, analysts anticipate that Insulet Co. will post 0.27 EPS for the current year.
In related news, Director Sally Crawford sold 28,347 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $108.60, for a total transaction of $3,078,484.20. Following the transaction, the director now directly owns 28,469 shares of the company’s stock, valued at approximately $3,091,733.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Charles Alpuche sold 3,900 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $104.78, for a total value of $408,642.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,289 shares of company stock worth $5,725,737. 3.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cresset Asset Management LLC purchased a new position in shares of Insulet during the 1st quarter valued at about $30,000. Manchester Capital Management LLC purchased a new position in shares of Insulet during the 1st quarter valued at about $31,000. Meridian Wealth Management LLC purchased a new position in shares of Insulet during the 1st quarter valued at about $48,000. PRW Wealth Management LLC purchased a new position in shares of Insulet during the 4th quarter valued at about $40,000. Finally, Tyers Asset Management LLC purchased a new position in shares of Insulet during the 1st quarter valued at about $49,000.
ILLEGAL ACTIVITY WARNING: “Insulet (NASDAQ:PODD) Reaches New 1-Year High at $115.61” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://transcriptdaily.com/2019/06/12/insulet-nasdaqpodd-reaches-new-1-year-high-at-115-61.html.
Insulet Company Profile (NASDAQ:PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Story: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.